My Inner State

← More articles

November 16, 2026 · 5 min read

Why the whole mushroom matters

Psilocybin comes from a mushroom, part of the same kingdom as reishi, lion's mane and shiitake. How women are using psilocybin mushrooms now, what research is asking, and why we think the whole mushroom deserves to be studied.

When people hear "psilocybin," most of them think "magic mushrooms." The two words have come to mean the same thing. But psilocybin is only one part of the mushroom. It's a single compound, and the mushroom that makes it is a whole living organism, with many other compounds of its own.

Psilocybin is only one part of the mushroom

Psilocybin mushrooms make a family of related compounds. Researchers have measured psilocybin alongside psilocin, baeocystin, norbaeocystin, aeruginascin and norpsilocin in the same mushrooms (Sharchaton and colleagues, 2026). The mushroom also builds up other compounds, including ergothioneine (Waldbillig and colleagues, 2023).

When we talk only about psilocybin, we're talking about one piece of something much bigger.

The entourage effect

The whole is more than the sum of its parts. In botanical science, that principle has a name: the entourage effect.

The term comes from cannabis research. In 1998, Raphael Mechoulam's lab showed that compounds with no measurable activity of their own made a related, active compound work more strongly (Ben-Shabat and colleagues, 1998). Researchers went on to explore how the many compounds in the cannabis plant work together (Russo, 2011). Across botanical research, scientists have documented synergy among the compounds inside a single plant extract. It's the basis for a long-held view: a whole extract can offer more than one isolated ingredient (Williamson, 2001).

We believe psilocybin mushrooms are no different, and the evidence points the same way:

  • Same psilocybin, stronger effect. In a 2024 mouse study, animals received either synthetic psilocybin or a whole-mushroom extract with the same dose of psilocybin. Psilocin levels in their blood were the same. Yet the extract produced a significantly more pronounced overall increase in brain proteins linked to plasticity, and the researchers concluded it had a more potent and prolonged effect than psilocybin alone.
  • The mushroom did what psilocybin alone didn't. In an earlier mouse study, a Psilocybe mushroom had a significantly stronger effect on a standard behavior test than the same dose of pure psilocybin.
  • The other compounds are active. In lab and rat studies, the active form of norbaeocystin switched on the same serotonin receptor as psilocybin's active form. In rats, norbaeocystin matched psilocybin on a standard mood-related behavior test, without the head-twitch response linked to psychedelic effects.
  • The chemistry lines up. A 2026 computer-modeling study found that several mushroom compounds bind stably to key brain targets, including that same serotonin receptor. The authors describe it as a mechanistic rationale for the stronger effects of whole-mushroom extracts over isolated psilocybin.

This work was done in animals and in the lab, and the next step is research in people. That's the work we're committed to. A single molecule tells you what one compound does. The whole mushroom shows you what nature actually made.

A kingdom of their own

To see why the whole matters, it helps to step back and remember what a mushroom is. Mushrooms aren't plants. Fungi are their own kingdom of life, and genetic evidence shows animals and fungi are each other's closest relatives (Baldauf and Palmer, 1993). As mycologist Paul Stamets put it in his 2008 TED talk, "we're more closely related to fungi than we are to any other kingdom."

Psilocybin mushrooms share that kingdom with mushrooms many of us already welcome into our lives. Shiitake is in the grocery store. Lion's mane and reishi show up in coffees and teas. Across Asia, reishi and cordyceps have long been part of traditional Chinese medicine (Paterson, 2008), and modern researchers study reishi for its many compounds, while noting that good human studies are still needed (Ahmad and colleagues, 2021). Psilocybin mushrooms aren't part of that tradition, but they are part of the same family of life.

Even the mushroom we see is only a small part of the organism. The page for Merlin Sheldrake's book Entangled Life describes mushrooms as "only fruiting bodies, analogous to apples on a tree." Most of a fungus lives out of sight as mycelium, a branching network of fine threads. Sheldrake's book explores how these networks connect living things, including the fungi that help make plant life possible. In the same talk, Stamets said he first proposed in the early 1990s "that mycelium is Earth's natural Internet."

We find that picture moving. A psilocybin mushroom grows out of a living network and carries the chemistry of the whole organism. That's a different starting point than a single molecule made in a lab.

How psilocybin mushrooms are used and studied now

Women are a big part of this story. In a global survey of more than 6,000 people who use psychedelics, 68.4% of those who only microdose were women, with an average age of 46.4. Psilocybin was the most common substance, and the most common reason for microdosing was general wellbeing.

Public programs are changing too. Oregon voters passed Measure 109 in 2020, and the Oregon Health Authority now licenses and regulates psilocybin services in the state.

Research is moving fastest on single, synthetic molecules, and two have now reached the application stage. In November 2026, Compass Pathways said it had completed its application for approval of COMP360, "its investigational synthetic, proprietary formulation of psilocybin," for treatment-resistant depression. The company expects to launch in the first half of 2027 if it's approved. The nonprofit Usona Institute has also completed an application, for its synthetic psilocybin in major depressive disorder, according to a November 2 report from Psychedelic Alpha. Usona hasn't commented publicly (industry coverage, November 2026). Neither has been approved yet.

That's real progress. Studying one pure compound is a sound way to learn what that compound does.

So there's a gap. Most of the research is about one compound. What many women actually use is the whole mushroom.

Where Inner State fits

We believe women deserve research on what they're actually using: the whole mushroom, not just one part of it. That's why we work with whole mushrooms, grown with care and studied with the same seriousness given to a single molecule.

Our first whole-mushroom product is investigational and is being studied through formal research. When you check in on My Inner State, your anonymous answers help show what women in perimenopause are experiencing, so this research starts from real lives.


For education only. Psilocybin is a Schedule I controlled substance under US federal law; its legal status varies by state and country. This article is not encouragement to obtain or use it, and is not medical advice. Inner State makes no claim that psilocybin, mushrooms or any compound mentioned here treats, cures or prevents any condition. If you're in crisis, call or text 988 in the US.

← More articles · Open my check-in